Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6535
    +0.0012 (+0.18%)
     
  • OIL

    83.66
    +0.09 (+0.11%)
     
  • GOLD

    2,349.60
    +7.10 (+0.30%)
     
  • Bitcoin AUD

    97,611.97
    -1,060.58 (-1.07%)
     
  • CMC Crypto 200

    1,327.60
    -68.94 (-4.94%)
     
  • AUD/EUR

    0.6108
    +0.0035 (+0.57%)
     
  • AUD/NZD

    1.0994
    +0.0037 (+0.33%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,718.30
    +287.79 (+1.65%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,239.66
    +153.86 (+0.40%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Cboe Global (CBOE) to Report Q3 Earnings: Is a Beat in Store?

Cboe Global Markets CBOE is slated to report third-quarter 2019 results on Nov 1, before market open. The company delivered positive earnings surprise in the last two reported quarters of 2019.

Let’s see how things have shaped up for this announcement.

Cboe Global’s third-quarter performance is likely to have benefited from strong market position and strength in its proprietary products, primarily SPX options, VIX options and VIX futures.

Acquisition of Bats Global is likely to have aided non-transactional revenue generating avenues.

Third-quarter revenues are expected to have benefited from proprietary market data and access and capacity fees. The Zacks Consensus Estimate for revenues is pegged at $284.2 million, indicating 5.1% increase from year-ago reported quarter figure.

CBOE Global estimates revenue per contract (RPC) for total options for the third quarter of 2019 to be 1% to 2% lower than 24.10 cents for the two months ended Aug 31, 2019. The RPC for futures is projected to be 0.5% to 1% higher than the two-month average of $1.783, indicating lower volume-related rebates in September.

Expenses are likely to have increased given several ongoing investments in systems hardware and software.

The Zacks Consensus Estimate for earnings is pegged at $1.15, indicating 5.2% increase from the year-ago period reported figure.

Cboe Global Markets, Inc. Price and EPS Surprise

Cboe Global Markets, Inc. Price and EPS Surprise
Cboe Global Markets, Inc. Price and EPS Surprise

Cboe Global Markets, Inc. price-eps-surprise | Cboe Global Markets, Inc. Quote

ADVERTISEMENT

What Our Quantitative Model States

Our proven model predicts an earnings beat for Cboe Global this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.

Earnings ESP: Cboe Global has an Earnings ESP of +0.72%. This is because the Most Accurate Estimate of $1.16 is pegged higher than the Zacks Consensus Estimate of $1.15. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: Cboe Global carries a Zacks Rank #3.

Other Stocks to Consider

Here are some other stocks from the finance sector with the perfect combination of elements to surpass estimates in their upcoming releases.

Intercontinental Exchange ICE is set to report third-quarter earnings on Oct 31. The stock has an Earnings ESP of +0.07% and a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Brighthouse Financial BHF is set to report third-quarter earnings on Nov 4. The stock has an Earnings ESP of +0.56% and a Zacks Rank #3.

Ares Management L.P. ARES is set to report third-quarter earnings on Oct 31. The stock has an Earnings ESP of +3.36% and a Zacks Rank of 3.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Ares Management L.P. (ARES) : Free Stock Analysis Report
 
Intercontinental Exchange Inc. (ICE) : Free Stock Analysis Report
 
Cboe Global Markets, Inc. (CBOE) : Free Stock Analysis Report
 
Brighthouse Financial, Inc. (BHF) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research